Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 16, 1998

View Archived Issues

Schering-Plough and Transgene gene delivery collaboration

Cyclooxygenase type 2, a potential therapeutic target in colon carcinogenesis

Efficacy of eliprodil and combination therapy in a rat embolic stroke model

Company Profile: Anergen

Variagenics granted U.S. patent covering Variagenic Targeting

Parkinson's patch yields positive results

SA-4503 may improve spatial learning performance in rats

JB-9315: a new H2 antagonist with both antisecretory and cytoprotective properties

Imiquimod for selftreatment of external anogenital warts

Vical and Centocor sign agreement for "naked" DNA technology

Amphocil marketing agreement signed for Mexico

Targretin demonstrates high preclinical efficacy in breast tumors

M2 ligands reported for the treatment of dementia

FDA approves CellCept for new indication

Hypocholesterolemic agents disclosed by Warner-Lambert

Orally active iron chelators in development at Novartis

Nonpeptide GnRH antagonists disclosed by Merck & Co.

CCKB/gastrin receptor antagonists with anxiolytic activity discovered at Rotta

Egis patents compounds affecting the central and peripheral serotonergic system

Trega and Ono expand R&D collaboration

KR-30450 exerts cardioprotective effects in ischemic rat hearts

New NSAID from Maruho and Toyama (M-5011) compares favorably with known compounds

Glaxo Wellcome to broaden HIV/AIDS drug pipeline

CDC advisory committee recommends rotavirus vaccine for routine use

Attenuation of AMPA receptor-mediated neurotoxicity by YM-90K

Micronized fenofibrate receives FDA approval

Progenitor discovers novel angiogenesis gene

More data on HMR's malononitrilamides presented at scientific congress

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...